Filing Flows › Maravai Lifesciences Holdings (MRVI) › Q3 2026 › vs Q2 2026
Maravai Lifesciences Holdings (MRVI) Q3 2026 vs Q2 2026 (quarter over quarter)
Maravai Lifesciences Holdings's revenue fell $5.6M (-11%) from $51.4M in Q2 2026 to $45.9M in Q3 2026. The biggest changes: TriLink −$6.3M (-18%); Cygnus +$728K (+4%).
Maravai Lifesciences Holdings, Q3 2026: revenue $45.9M (+10% year over year), operating margin -45.0%, net loss $24.0M, operating cash flow $5.0M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Free cash flow margin | 9.8% | 7.0% | +2.8 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| TriLink | $28.4M | $34.7M | −$6.3M | -18% |
| Cygnus | $17.5M | $16.8M | $728K | +4% |
| Revenue | $45.9M | $51.4M | −$5.6M | -11% |
| Income tax benefit | $75K | $171K | −$96K | -56% |
| Net loss | $24.0M | $21.6M | $2.4M | +11% |
| Costs & expenses | $69.9M | $73.2M | −$3.3M | -5% |
| Operating costs | $66.5M | $66.5M | −$61K | -0.1% |
| Interest & other, net | $3.5M | $6.7M | −$3.3M | -49% |
| Cost of revenue | $29.7M | $30.8M | −$1.1M | -4% |
| Research & development | $3.4M | $3.7M | −$312K | -8% |
| SG&A | $30.5M | $32.1M | −$1.6M | -5% |
| Operating cash sources | $29.0M | $25.6M | $3.4M | +13% |
| Depreciation & amortization | $12.2M | $11.8M | $421K | +4% |
| Share-based compensation | $10.1M | $10.2M | −$90K | -0.9% |
| Working capital & other | $6.7M | $3.6M | $3.1M | +84% |
| Net loss absorbed | $24.0M | $21.6M | $2.4M | +11% |
| Operating cash flow | $5.0M | $4.0M | $1.0M | +26% |
| Free cash flow (OCF − capex) | $4.5M | $3.6M | $870K | +24% |
| Capital expenditures | $523K | $370K | $153K | +41% |
Questions
How much did Maravai Lifesciences Holdings's revenue grow quarter over quarter in Q3 2026?
Maravai Lifesciences Holdings's revenue fell $5.6M (-11%) from $51.4M in Q2 2026 to $45.9M in Q3 2026.
What drove Maravai Lifesciences Holdings's revenue change in Q3 2026?
TriLink −$6.3M (-18%); Cygnus +$728K (+4%).